$ACXP News

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

FDA Conditionally Accepts Acurx Pharmaceuticals' Brand Name CIFBEZY for Ibezapolstat

Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Acurx Pharmaceuticals Announces Intent For Further Discussion With FDA Regarding Ibezapolstat's Phase 3 Clinical Program, Scope Of Its Planned NDA

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat

Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) Q1 Results Beat Estimates as Pipeline Advances Steadily

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026